<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609855</url>
  </required_header>
  <id_info>
    <org_study_id>HBB-1</org_study_id>
    <nct_id>NCT01609855</nct_id>
  </id_info>
  <brief_title>Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate?</brief_title>
  <official_title>Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valduce Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valduce Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study was to test if the administration of Hyoscine Butyl Bromide, at
      time of caecal intubation, increases the adenoma detection rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outpatients referred for colonoscopy were screened for possible enrollment. Exclusion
      criteria included: glaucoma, benign prostatic hyperplasia or urinary obstruction, previous
      intestinal resection, ongoing therapy with tricyclic antidepressants, chronic renal failure
      and history of IBD. Eligible patients were randomized to receive either 20 mg/2ml of HBB i.v.
      or 2ml of saline i.v.; both the endoscopist and the patient were blind to the administered
      drug. The endoscopist was asked to inspect the right, transverse and left colon for at least
      2 min for each segment. The number, size and location of polyps were recorded as well as the
      occurrence episodes of tachycardia (defined as bpm&gt;140). As indirect estimation of the amount
      of air retained in the abdomen at the end of the procedure, the DAC (difference in the
      abdominal circumference measured before and after colonoscopy) was also calculated. At
      discharge (at least 1 hour after colonoscopy) the bloating perceived by the patient was
      measured by means of a VA scale (range 0-100).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Hyoscine Butyl Bromide on Adenoma Detection Rate (ADR)</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of HBB</measure>
    <time_frame>this outcome will be evaluated at the end of colonoscopy</time_frame>
    <description>As indirect estimation of the amount of air retained in the abdomen at the end of the procedure, the DAC (difference in the abdominal circumference measured before and after colonoscopy) was also calculated. At discharge (at least 1 hour after colonoscopy) the bloating perceived by the patient was measured by means of a VA scale (range 0-100).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Colonic Adenomas</condition>
  <arm_group>
    <arm_group_label>HBB- Hioscine Butyl Bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine Butyl Bromide 20mg/2 ml i.v.</intervention_name>
    <description>Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation</description>
    <arm_group_label>HBB- Hioscine Butyl Bromide</arm_group_label>
    <other_name>Buscopan: Hyoscine Butyl Bromide 20mg/2 ml i.v.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 2 ml i.v.</intervention_name>
    <description>Administration of Saline 2 ml at time of caecal intubation</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  outpatients referred for colonoscopy

        Exclusion Criteria:

          -  glaucoma

          -  benign prostatic hyperplasia or urinary obstruction

          -  previous intestinal resection,

          -  ongoing therapy with tricyclic antidepressants

          -  chronic renal failure

          -  history of IBD

          -  participation other studies

          -  unsedated colonoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spinzi Giancarlo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gastroenterology Unit, Ospedale Valduce, Como, Italy.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Radaelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gastroenterology Unit, Ospedale Valduce, Como. Italy.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emanuele Rondonotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology Unit, Ospedale Valduvce, Como. Italy.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuele Rondonotti, MD</last_name>
    <phone>0039031324145</phone>
    <email>ema.rondo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale Valduce</name>
      <address>
        <city>Como</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gianni Imperiali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vittorio Terruzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanna Mandelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Paggi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicoletta Lenoci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaldo Amato, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia Terreni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Valduce</name>
      <address>
        <city>Como</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spinzi Giancarlo, MD</last_name>
      <phone>0039031324141</phone>
      <email>gispinz@tin.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2012</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Valduce Hospital</investigator_affiliation>
    <investigator_full_name>Emanuele Rondonotti</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Adenoma Detection Rate</keyword>
  <keyword>Anti-spasmotic drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

